Aspirin for prevention of preeclampsia in lupus pregnancy

Autoimmune Diseases

Volumn 2014, Issue , 2014, Pages

  Schramm, Amelie M ^a   Clowse, Megan E B ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENIC FACTOR; CYCLOOXYGENASE 1; HEPARIN; INTERLEUKIN 6; INTERLEUKIN 8; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INFLAMMATION; LOW DRUG DOSE; META ANALYSIS (TOPIC); PLACENTA DISORDER; PLACENTA PERFUSION; PLACENTAL VASCULAR REMODELING; PREECLAMPSIA; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VASCULARIZATION;

EID: 84897563740     PISSN: None     EISSN: 20900430     Source Type: Journal    
DOI: 10.1155/2014/920467     Document Type: Review

References (45)

1. Shennan A., Luesley D. M., Baker P. N., Preeclampsia and non-proteinuric pregnancy-induced hypertension. Obstetrica and Gynaenocology: An Evidence-Based Text for MRCOG 2004 London, UK Arnold 179 186
2. Clowse M. E. B., Lupus activity in pregnancy. Rheumatic Disease Clinics of North America 2007 33 2 237 252 2-s2.0-34248176839 10.1016/j.rdc.2007.01.002 (Pubitemid 46710328)
3. Ji L., Brkić J., Liu M., Fu G., Peng C., Wang Y. L., Placental trophoblast cell differentiation: physiological regulation and pathological relevance to preeclampsia. Molecular Aspects of Medicine 2012 34 5 981 1023
4. Stillman I. E., Karumanchi S. A., The glomerular injury of preeclampsia. Journal of the American Society of Nephrology 2007 18 8 2281 2284 2-s2.0-34547632121 10.1681/ASN.2007020255 (Pubitemid 47203843)
5. Valdés G., Corthorn J., Review: the angiogenic and vasodilatory utero-placental network. Placenta 2011 32 supplement 2 S170 S175 2-s2.0-79952005383 10.1016/j.placenta.2011.01.008
6. Di Marco G. S., Reuter S., Hillebrand U., Amler S., König M., Larger E., Oberleithner H., Brand E., Pavenstädt H., Brand M., The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. Journal of the American Society of Nephrology 2009 20 10 2235 2245 2-s2.0-70349895636 10.1681/ASN.2009010061
7. Bergmann A., Ahmad S., Cudmore M., Gruber A. D., Wittschen P., Lindenmaier W., Christofori G., Gross V., Gonzalves A. C. D. C., Gröne H.-J., Ahmed A., Weich H. A., Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. Journal of Cellular and Molecular Medicine 2010 14 6 B 1857 1867 2-s2.0-77955145573 10.1111/j.1582-4934.2009. 00820.x
8. Wu F. T. H., Stefanini M. O., Gabhann F. M., Kontos C. D., Annex B. H., Popel A. S., A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. Journal of Cellular and Molecular Medicine 2010 14 3 528 552 2-s2.0-77952593669 10.1111/j.1582-4934.2009.00941.x
9. Hirashima C., Ohkuchi A., Matsubara S., Suzuki H., Takahashi K., Usui R., Suzuki M., Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. Hypertension Research 2008 31 8 1541 1548 2-s2.0-55449093771
10. Romero R., Nien J. K., Espinoza J., Todem D., Fu W., Chung H., Kusanovic J. P., Gotsch F., Erez O., Mazaki-Tovi S., Gomez R., Edwin S., Chaiworapongsa T., Levine R. J., Karumanchi S. A., A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. Journal of Maternal-Fetal and Neonatal Medicine 2008 21 1 9 23 2-s2.0-37849021866 10.1080/14767050701830480
11. Lim J. H., Kim S. Y., Park S. Y., Yang J. H., Kim M. Y., Ryu H. M., Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstetrics and Gynecology 2008 111 6 1403 1409
12. Jacobs M., Nassar N., Roberts C. L., Hadfield R., Morris J. M., Ashton A. W., Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. Reproductive Biology and Endocrinology 2011 9, article 77 2-s2.0-79958070460 10.1186/1477-7827-9-77
13. Odibo A. O., Rada C. C., Cahill A. G., Goetzinger K. R., Tuuli M. G., Odibo L., Macones G. A., England S. K., First-trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia. Journal of Perinatology 2013 33 9 670 674 10.1038/jp.2013.33
14. Qazi U., Lam C., Karumanchi S. A., Petri M., Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. Journal of Rheumatology 2008 35 4 631 634 2-s2.0-41849092309 (Pubitemid 351500058)
15. Duley L., Henderson-Smart D. J., Meher S., King J. F., Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database of Systematic Reviews 2007 2 CD004659 2-s2.0-34447308555
16. Trivedi N. A., A meta-analysis of low-dose aspirin for prevention of preeclampsia. Journal of Postgraduate Medicine 2011 57 2 91 95 2-s2.0-80052210115 10.4103/0022-3859.81858
17. Roberge S., Villa P., Nicolaides K., Giguére Y., Vainio M., Bakthi A., Ebrashy A., Bujold E., Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagnosis and Therapy 2012 31 3 141 146 2-s2.0-84860323582 10.1159/000336662
18. Villa P. M., Kajantie E., Räikkönen K., Pesonen A. K., Hämäläinen E., Vainio M., Taipale P., Laivuori H., Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. British Journal of Obstetrics and Gynaecology 2013 120 1 64 74
19. Szarka A., Rigó J. Jr., Lázár L., Beko G., Molvarec A., Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunology 2010 11, article 59 2-s2.0-78649590865 10.1186/1471-2172-11-59
20. Kingdom J. C. P., Drewlo S., Is heparin a placental anticoagulant in high-risk pregnancies? Blood 2011 118 18 4780 4788 2-s2.0-80855133521 10.1182/blood-2011-07-319749
21. Ramma W., Ahmed A., Is inflammation the cause of pre-eclampsia? Biochemical Society Transactions 2011 39 6 1619 1627 2-s2.0-81855218052 10.1042/BST20110672
22. Groeneveld E., Lambers M. J., Lambalk C. B., Broeze K. A., Haapsamo M., de Sutter P., Schoot B. C., Schats R., Mol B. W., Hompes P. G., Preconceptional low-dose aspirin for the prevention of hypertensive pregnancy complications and preterm delivery after IVF: a meta-analysis with individual patient data. Human Reproduction 2013 28 6 1480 1488 10.1093/humrep/det022
23. Schiff E., Peleg E., Goldenberg M., Rosenthal T., Ruppin E., Tamarkin M., Barkai G., Ben-Baruch G., Yahal I., Blankstein J., Goldman B., Mashiach S., The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. New England Journal of Medicine 1989 321 6 351 356 2-s2.0-0024345994 (Pubitemid 19190439)
24. Rahman A., Isenberg D. A., Systemic lupus erythematosus. New England Journal of Medicine 2008 358 9 929 939 2-s2.0-40049093765 10.1056/NEJMra071297 (Pubitemid 351397092)
25. Silva C. A. A., Leal M. M., Leone C., Simone V. P., Takiuti A. D., Saito M. I., Kiss M. H. B., Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus 2002 11 7 419 425 2-s2.0-0036024148 10.1191/0961203302lu219oa
26. Clowse M. E. B., Jamison M., Myers E., James A. H., A national study of the complications of lupus in pregnancy. The American Journal of Obstetrics and Gynecology 2008 199 2 127.e1 127.e6 2-s2.0-47949126782 10.1016/j.ajog.2008.03. 012
27. Erkan D., Sammaritano L., New insights into pregnancy-related complications in systemic lupus erythematosus. Current Rheumatology Reports 2003 5 5 357 363 2-s2.0-1542705888
28. Bramham K., Hunt B. J., Bewley S., Germain S., Calatayud I., Khamashta M. A., Nelson-Piercy C., Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. Journal of Rheumatology 2011 38 9 1906 1913 2-s2.0-80052330437 10.3899/jrheum.100997
29. Chakravarty E. F., Colón I., Langen E. S., Nix D. A., El-Sayed Y. Y., Genovese M. C., Druzin M. L., Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. The American Journal of Obstetrics and Gynecology 2005 192 6 1897 1904 2-s2.0-20444433640 10.1016/j.ajog.2005.02.063 (Pubitemid 40827062)
30. Santos M. J., Carmona-Fernandes D., Canhão H., Canas da Silva J., Fonseca J. E., Gil V., Early vascular alterations in SLE and RA patients-a step towards understanding the associated cardiovascular risk. PLoS ONE 2012 7 9 e44668
31. Haque S., Alexander M. Y., Bruce I. N., Endothelial progenitor cells: a new player in lupus? Arthritis Research and Therapy 2012 14 1, article 203 2-s2.0-84857368358 10.1186/ar3700
32. Santner-Nanan B., John Peek M., Khanam R., Richarts L., Zhu E., Fazekas De St Groth B., Nanan R., Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. Journal of Immunology 2009 183 11 7023 7030 2-s2.0-73349085587 10.4049/jimmunol.0901154
33. Becker-Merok A., Eilertsen G. Ø., Nossent J. C., Levels of transforming growth factor- β are low in systemic lupus erythematosus patients with active disease. Journal of Rheumatology 2010 37 10 2039 2045 2-s2.0-77957870728 10.3899/jrheum.100180
34. Wong C. K., Lit L. C. W., Tam L. S., Li E. K. M., Wong P. T. Y., Lam C. W. K., Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clinical Immunology 2008 127 3 385 393 2-s2.0-45249097325 10.1016/j.clim.2008. 01.019
35. Alunno A., Bartoloni E., Bistoni O., Nocentini G., Ronchetti S., Caterbi S., Valentini V., Riccardi C., Gerli R., Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clinical and Developmental Immunology 2012 2012 5 823085 10.1155/2012/823085
36. Tower C., Mathen S., Crocker I., Bruce I. N., Regulatory T cells in systemic lupus erythematosus and pregnancy. The American Journal of Reproductive Immunology 2013 69 6 588 595
37. Duckitt K., Harrington D., Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. British Medical Journal 2005 330 7491 565 567 2-s2.0-15044344544 10.1136/bmj.38380.674340.E0 (Pubitemid 40380349)
38. Abrahams V. M., Mechanisms of antiphospholipid antibody-associated pregnancy complications. Thrombosis Research 2009 124 5 521 525 2-s2.0-70349880351 10.1016/j.thromres.2009.07.011
39. Chen Q., Guo F., Hensby-Bennett S., Stone P., Chamley L., Antiphospholipid antibodies prolong the activation of endothelial cells induced by necrotic trophoblastic debris: implications for the pathogenesis of preeclampsia. Placenta 2012 33 10 810 815 10.1016/j.placenta.2012.07.019
40. Gómez-Puerta J. A., Cervera R., Espinosa G., Asherson R. A., García-Carrasco M., Da Costa I. P., Andrade D. C. O., Borba E. F., Makatsaria A., Bucciarelli S., Ramos-Casals M., Font J., Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Annals of the Rheumatic Diseases 2007 66 6 740 746 2-s2.0-34249806311 10.1136/ard.2006.061671 (Pubitemid 46846692)
41. Committee on Practice Bulletins-Obstetrics, American College of Obstetricians and Gynecologists, Practice Bulletin No. 132: antiphospholipid syndrome. Obstetrics and Gynecology 2012 120 6 1514 1521
42. Wijetilleka S., Scoble T., Khamashta M., Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome. Current Opinion in Rheumatology 2012 24 5 473 481 10.1097/BOR.0b013e328354ae8c
43. Yurdakok M., Fetal and neonatal effects of anticoagulants used in pregnancy: a review. The Turkish Journal of Pediatrics 2012 54 3 207 215
44. Nørgård B., Puhó E., Czeizel A. E., Skriver M. V., Sørensen H. T., Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. The American Journal of Obstetrics and Gynecology 2005 192 3 922 923 2-s2.0-14644411043 10.1016/j.ajog.2004.10.598 (Pubitemid 40311290)
45. Di Sessa T. G., Moretti M. L., Khoury A., Pulliam D. A., Arheart K. L., Sibai B. M., Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. The American Journal of Obstetrics and Gynecology 1994 171 4 892 900 2-s2.0-0028027559 (Pubitemid 24341466)